Raymond James & Associates Boosts Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Raymond James & Associates lifted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 34.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 222,369 shares of the company’s stock after buying an additional 57,134 shares during the quarter. Raymond James & Associates’ holdings in Takeda Pharmaceutical were worth $3,173,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of TAK. Point72 Asset Management L.P. purchased a new stake in shares of Takeda Pharmaceutical in the 4th quarter valued at $43,410,000. Millennium Management LLC raised its holdings in shares of Takeda Pharmaceutical by 124.1% in the 4th quarter. Millennium Management LLC now owns 2,238,381 shares of the company’s stock valued at $34,919,000 after buying an additional 1,239,382 shares during the period. BlackRock Inc. raised its holdings in shares of Takeda Pharmaceutical by 38.6% in the 1st quarter. BlackRock Inc. now owns 3,021,274 shares of the company’s stock valued at $43,265,000 after buying an additional 842,139 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Takeda Pharmaceutical by 13.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,242,689 shares of the company’s stock valued at $60,755,000 after buying an additional 509,886 shares during the period. Finally, Kayne Anderson Rudnick Investment Management LLC purchased a new stake in shares of Takeda Pharmaceutical in the 1st quarter valued at $7,800,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Insiders Place Their Bets

In other Takeda Pharmaceutical news, major shareholder Pharmaceutical Co Ltd Takeda sold 3,703,703 shares of the company’s stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $8.10, for a total transaction of $29,999,994.30. Following the sale, the insider now owns 3,755,583 shares in the company, valued at approximately $30,420,222.30. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.04% of the stock is owned by company insiders.

Takeda Pharmaceutical Price Performance

TAK stock opened at $13.37 on Friday. The business’s fifty day moving average price is $14.27 and its 200 day moving average price is $14.33. The company has a current ratio of 1.06, a quick ratio of 0.55 and a debt-to-equity ratio of 0.64. Takeda Pharmaceutical Company Limited has a 12-month low of $13.19 and a 12-month high of $17.11. The company has a market capitalization of $42.31 billion, a PE ratio of 20.26, a P/E/G ratio of 3.84 and a beta of 0.53.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, February 1st. The company reported $0.51 earnings per share for the quarter. Takeda Pharmaceutical had a return on equity of 12.57% and a net margin of 6.90%. The company had revenue of $7.52 billion for the quarter. On average, sell-side analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.5 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.